|Articles|April 1, 2020
- Pharmaceutical Executive-04-01-2020
- Volume 40
- Issue 4
Pharmaceutical Executive, April 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
HBA's Woman of the Year 2020: A Motivated Missionover 5 years ago
Doubling Down on D&Iover 5 years ago
COVID-19 Ripple Effects for Pharmaover 5 years ago
Prescribing Patterns: How to Get Ahead of the Trendsover 5 years ago
There’s No Easing the Price-vs.-Value Debateover 5 years ago
Payer Perspectives on Gene Therapy Reimbursementover 5 years ago
Covid-19 Pandemic Thrusts Biopharma R&D to Forefrontover 5 years ago
Transforming the CIO Role to Embrace Digital Healthover 5 years ago
Country Report: The Czech RepublicNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
4
Invictus Pharmacy Becomes First US Pharmacy to Accept Cryptocurrency for Prescriptions
5
